Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, Barry WT, Goel S, Lahdenrata J, Isakoff SJ, Yeh ED, Jain SR, Golshan M, Brock J, Snuderl M, Winer EP, Krop IE, Jain RK. Tolaney SM, et al. Among authors: ancukiewicz m. Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14325-30. doi: 10.1073/pnas.1518808112. Epub 2015 Nov 2. Proc Natl Acad Sci U S A. 2015. PMID: 26578779 Free PMC article. Clinical Trial.
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.
Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Huang Y, et al. Among authors: ancukiewicz m. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. doi: 10.1073/pnas.1215397109. Epub 2012 Oct 8. Proc Natl Acad Sci U S A. 2012. PMID: 23045683 Free PMC article.
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Batchelor TT, et al. Among authors: ancukiewicz m. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19059-64. doi: 10.1073/pnas.1318022110. Epub 2013 Nov 4. Proc Natl Acad Sci U S A. 2013. PMID: 24190997 Free PMC article. Clinical Trial.
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Heist RS, et al. Among authors: ancukiewicz m. Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1547-52. doi: 10.1073/pnas.1424024112. Epub 2015 Jan 20. Proc Natl Acad Sci U S A. 2015. PMID: 25605928 Free PMC article. Clinical Trial.
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Willett CG, et al. Among authors: ancukiewicz m. J Clin Oncol. 2009 Jun 20;27(18):3020-6. doi: 10.1200/JCO.2008.21.1771. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470921 Free PMC article. Clinical Trial.
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. Sorensen AG, et al. Among authors: ancukiewicz m. Cancer Res. 2009 Jul 1;69(13):5296-300. doi: 10.1158/0008-5472.CAN-09-0814. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549889 Free PMC article.
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK. Xu L, et al. Among authors: ancukiewicz m. Cancer Res. 2009 Oct 15;69(20):7905-10. doi: 10.1158/0008-5472.CAN-09-2099. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826039 Free PMC article.
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK. Duda DG, et al. Among authors: ancukiewicz m. Oncologist. 2010;15(6):577-83. doi: 10.1634/theoncologist.2010-0029. Epub 2010 May 18. Oncologist. 2010. PMID: 20484123 Free PMC article. Clinical Trial.
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Chung DC, Clark JW, Jain RK. Willett CG, et al. Among authors: ancukiewicz m. Oncologist. 2010;15(8):845-51. doi: 10.1634/theoncologist.2010-0030. Epub 2010 Jul 28. Oncologist. 2010. PMID: 20667969 Free PMC article. Clinical Trial.
114 results